tcn-032
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Sep 1, 2011 (NCT01390025)
Timeline
Indications
Studied for
Mechanism of action
- Matrix protein 2INHIBITOR
M2 inhibitor
- Influenza virusImmunity, passive
Influenza virus immunity, passive
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2109619 ↗
Also known as
- tcn-032
- tcn-032
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01719874 | Phase 2 | Aug 1, 2012 | Theraclone Sciences, Inc. |
| NCT01390025 | Phase 1 | Sep 1, 2011 | Shin Nippon Biomedical Laboratories, Theraclone Sciences, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Theraclone Sciences, Inc. | For profit | 2 | 2 | 2 | 2011 |
| Shin Nippon Biomedical Laboratories | For profit | 1 | 0 | 1 | 2011 |
2 organizations
Page 1 / 1